Oral type II collagen in JRA

Linda Myers, G. Higgins, J. Thomson, C. Walton, J. Hendricks, N. Kerr, R. Pandya, B. Shlopov, J. M. Seyer, Arnold Postlethwaite, Andrew Kang

Research output: Contribution to journalArticle

Abstract

Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to a cartilage-specific protein, namely, collagen type II (CII). In order to test the hypothesis that downregulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open label study of oral CII was performed in nine patients with JRA. Seven polyarticular (RF negative) and two pauciarticular (early onset) JRA patients were treated for one month with 100 μg/day of bovine CII, followed by two months of 500 μg/day. Two of the patients flared when the treatment was discontinued and were retreated for an additional period of six months. Patients were evaluated for disease activity and for routine laboratory examinations at monthly intervals. Out of the eleven, eight fit the criteria for clinical improvement as outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. We propose that oral tolerance induces an immune deviation so that T cells produce a Th2-type cytokines which down-regulate inflammation and autoimmune arthritis. To test this hypothesis, PBL's from patients were collected before and after therapy with CII, cultured with CII, and supernatants were collected and analyzed for various cytokines by ELISA. In six of the eight patients who improved, interferon gamma production decreased after oral CII therapy. In three patients that did not show a clinical improvement, interferon gamma production increased. Although this was an open label trial, these results are encouraging. More studies will be needed to establish the efficacy of this treatment protocol. In summary, our study suggests that oral CII might be effective in treatment of JRA and deserves further investigation.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume47
Issue number2
StatePublished - Jan 1 1999

Fingerprint

Collagen Type II
Juvenile Arthritis
Autoimmunity
Interferon-gamma
Labels
Down-Regulation
Cytokines
Inflammation
Therapeutics
Immune Tolerance
T-cells
Cartilage
Clinical Protocols
Arthritis
Oral Administration
Joints
Enzyme-Linked Immunosorbent Assay
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Myers, L., Higgins, G., Thomson, J., Walton, C., Hendricks, J., Kerr, N., ... Kang, A. (1999). Oral type II collagen in JRA. Journal of Investigative Medicine, 47(2).

Oral type II collagen in JRA. / Myers, Linda; Higgins, G.; Thomson, J.; Walton, C.; Hendricks, J.; Kerr, N.; Pandya, R.; Shlopov, B.; Seyer, J. M.; Postlethwaite, Arnold; Kang, Andrew.

In: Journal of Investigative Medicine, Vol. 47, No. 2, 01.01.1999.

Research output: Contribution to journalArticle

Myers, L, Higgins, G, Thomson, J, Walton, C, Hendricks, J, Kerr, N, Pandya, R, Shlopov, B, Seyer, JM, Postlethwaite, A & Kang, A 1999, 'Oral type II collagen in JRA', Journal of Investigative Medicine, vol. 47, no. 2.
Myers L, Higgins G, Thomson J, Walton C, Hendricks J, Kerr N et al. Oral type II collagen in JRA. Journal of Investigative Medicine. 1999 Jan 1;47(2).
Myers, Linda ; Higgins, G. ; Thomson, J. ; Walton, C. ; Hendricks, J. ; Kerr, N. ; Pandya, R. ; Shlopov, B. ; Seyer, J. M. ; Postlethwaite, Arnold ; Kang, Andrew. / Oral type II collagen in JRA. In: Journal of Investigative Medicine. 1999 ; Vol. 47, No. 2.
@article{b8b879bd22204d419fa73416f13a8663,
title = "Oral type II collagen in JRA",
abstract = "Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to a cartilage-specific protein, namely, collagen type II (CII). In order to test the hypothesis that downregulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open label study of oral CII was performed in nine patients with JRA. Seven polyarticular (RF negative) and two pauciarticular (early onset) JRA patients were treated for one month with 100 μg/day of bovine CII, followed by two months of 500 μg/day. Two of the patients flared when the treatment was discontinued and were retreated for an additional period of six months. Patients were evaluated for disease activity and for routine laboratory examinations at monthly intervals. Out of the eleven, eight fit the criteria for clinical improvement as outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. We propose that oral tolerance induces an immune deviation so that T cells produce a Th2-type cytokines which down-regulate inflammation and autoimmune arthritis. To test this hypothesis, PBL's from patients were collected before and after therapy with CII, cultured with CII, and supernatants were collected and analyzed for various cytokines by ELISA. In six of the eight patients who improved, interferon gamma production decreased after oral CII therapy. In three patients that did not show a clinical improvement, interferon gamma production increased. Although this was an open label trial, these results are encouraging. More studies will be needed to establish the efficacy of this treatment protocol. In summary, our study suggests that oral CII might be effective in treatment of JRA and deserves further investigation.",
author = "Linda Myers and G. Higgins and J. Thomson and C. Walton and J. Hendricks and N. Kerr and R. Pandya and B. Shlopov and Seyer, {J. M.} and Arnold Postlethwaite and Andrew Kang",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
volume = "47",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Oral type II collagen in JRA

AU - Myers, Linda

AU - Higgins, G.

AU - Thomson, J.

AU - Walton, C.

AU - Hendricks, J.

AU - Kerr, N.

AU - Pandya, R.

AU - Shlopov, B.

AU - Seyer, J. M.

AU - Postlethwaite, Arnold

AU - Kang, Andrew

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to a cartilage-specific protein, namely, collagen type II (CII). In order to test the hypothesis that downregulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open label study of oral CII was performed in nine patients with JRA. Seven polyarticular (RF negative) and two pauciarticular (early onset) JRA patients were treated for one month with 100 μg/day of bovine CII, followed by two months of 500 μg/day. Two of the patients flared when the treatment was discontinued and were retreated for an additional period of six months. Patients were evaluated for disease activity and for routine laboratory examinations at monthly intervals. Out of the eleven, eight fit the criteria for clinical improvement as outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. We propose that oral tolerance induces an immune deviation so that T cells produce a Th2-type cytokines which down-regulate inflammation and autoimmune arthritis. To test this hypothesis, PBL's from patients were collected before and after therapy with CII, cultured with CII, and supernatants were collected and analyzed for various cytokines by ELISA. In six of the eight patients who improved, interferon gamma production decreased after oral CII therapy. In three patients that did not show a clinical improvement, interferon gamma production increased. Although this was an open label trial, these results are encouraging. More studies will be needed to establish the efficacy of this treatment protocol. In summary, our study suggests that oral CII might be effective in treatment of JRA and deserves further investigation.

AB - Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to a cartilage-specific protein, namely, collagen type II (CII). In order to test the hypothesis that downregulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open label study of oral CII was performed in nine patients with JRA. Seven polyarticular (RF negative) and two pauciarticular (early onset) JRA patients were treated for one month with 100 μg/day of bovine CII, followed by two months of 500 μg/day. Two of the patients flared when the treatment was discontinued and were retreated for an additional period of six months. Patients were evaluated for disease activity and for routine laboratory examinations at monthly intervals. Out of the eleven, eight fit the criteria for clinical improvement as outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. We propose that oral tolerance induces an immune deviation so that T cells produce a Th2-type cytokines which down-regulate inflammation and autoimmune arthritis. To test this hypothesis, PBL's from patients were collected before and after therapy with CII, cultured with CII, and supernatants were collected and analyzed for various cytokines by ELISA. In six of the eight patients who improved, interferon gamma production decreased after oral CII therapy. In three patients that did not show a clinical improvement, interferon gamma production increased. Although this was an open label trial, these results are encouraging. More studies will be needed to establish the efficacy of this treatment protocol. In summary, our study suggests that oral CII might be effective in treatment of JRA and deserves further investigation.

UR - http://www.scopus.com/inward/record.url?scp=33750120710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750120710&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750120710

VL - 47

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 2

ER -